The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

"Treatment-resistant depression can be very complicated ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray ... treatment is poised to change the landscape of depression management, particularly for those grappling ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...

“Treatment-resistant depression can be very complicated ... symptom improvement,” the statement quoted Bill Martin of Johnson & Johnson and saying. “With Spravato now approved as a stand ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...